New Blog Post and Upcoming Journal Family Webinars
The ASCPT Journal Family is excited to present a new post on PSPod and two upcoming webinars focused on transporters.
PSP Highlights New FDA Guidance
Associate Editors Ping Zhao, PhD, and Vikram Sinha, PhD, take a look at the recently finalized Physiologically Based Pharmacokinetic (PBPK) guidance from the US Food and Drug Administration.
Check out the full post, Recent Guidance on Physiologically Based Pharmacokinetic Models: Heralding Standardization and Consistency in Submissions
, for a breakdown of what has been included in the final version and how useful PBPK has become in recent years.
Don’t Miss These Exciting Webinars from CPT!
There’s still time to register for these great presentations, so mark your calendar:
: Changes in Expression and Activity of Transporters in Disease: Do They Impact Pharmacokinetics and Toxicity of Drugs?
Date and Time
: November 29, 2018 12:00 PM EST
: Raymond Evers, PhD, and Jason Sprowl, PhD
: Saskia de Wildt, MD, PhD
: Transporters play a critical role in the ADME of many drugs and endogenous compounds. Disruption of these pathways can have a profound effect on overall physiology, or drug pharmacokinetics, efficacy, and toxicity. Join Drs. Evers and Sprowl as they provide an overview of changes in transporter function associated with acute and chronic disease states, and regulatory pathways affecting transporter expression. In addition, they will discuss how mechanistic understanding in the role of transporters in drug disposition can aid in alleviating transporter-mediated toxic effects.
: 2018 ITC Update on Clinically-Relevant Transporters, Clinical Probes, and DDI Evaluation
Date and Time
: December 7, 2018 12:00 PM EST
: Maciej Zamek-Gliszczynski, PhD
: Shuiying Hu, PhD
: Join this ASCPT Journal Family webinar as Maciej Zamek-Gliszczynski, PhD, summarizes the state-of-the-art in transporters in drug development based on four recent International Transporter Consortium whitepapers recently published in Clinical Pharmacology & Therapeutics
(Vol 104, Iss 5). A practical overview of emerging transporters of clinical relevance will be provided (e.g., OCT1, OATP2B1, etc.). Best practice in design of clinical DDI studies will be illustrated with recent advances in the study of OCT1, P-gp, and BCRP. Lastly, considerations for optimal selection of clinical probe drugs, including future potential utility of transporter biomarkers, will be discussed.